Validity and Cost-Effectiveness of a New Screening Test for Hepatocellular Carcinoma

Chinese University of Hong Kong1,018 enrolled

Overview

The purpose of this study is: 1. To establish and compare the diagnostic utilities for hepatocellular carcinoma (HCC) screening tests of (a) HS-AFP, (b) AFP + US,(c) AFP alone and (d) US alone (within HBV carriers between age 40 and 70 years); 2. To establish the cost-effectiveness of the screening tests; 3. To compare tumor sizes, resection rates, and survival rates up to 18 months between those who were screened by HS-AFP those of a historical control group that was not screened.

Study Type

OBSERVATIONAL

Enrollment

1,018

Conditions

Hepatitis B Virus

Eligibility

Sex: ALLMin age: 40 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age between 40 and 70 years * Seropositive for HBsAg * Child's A or B * Life expectancy of more than 2 years Exclusion Criteria: * Non-HBV related cirrhosis * History of malignancy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.